The FDA has approved Journavx, a new non-opioid painkiller designed to treat moderate to severe acute pain. Unlike opioids, Journavx works directly at the site of pain, blocking nerve signals before they reach the brain. This approach aims to reduce the risk of addiction associated with opioids, which affect brain reward centers.
Experts like Dr. Deborah Mann and addiction advocate Colleen Buxton see the approval as a significant step in combating opioid dependency. With opioids linked to addiction in up to 19% of patients, minimizing their use could lead to fewer overdose deaths.
While Journavx addresses acute pain, doctors hope for future innovations targeting chronic pain as well.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to news@fingerlakes1.com.